Randomized, Double-blind, Placebo-controlled Trial on the Effectiveness and Safety of Dapagliflozin for Blood Glucose Control During Glucocorticoid Treatment for Acute Exacerbation COPD
Phase of Trial: Phase IV
Latest Information Update: 28 May 2018
Price : $35 *
At a glance
- Drugs Dapagliflozin (Primary) ; Insulin
- Indications Hyperglycaemia
- Focus Adverse reactions; Therapeutic Use
- 19 May 2018 Status changed from active, no longer recruiting to completed.
- 15 Sep 2017 Results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
- 09 Mar 2017 Planned End Date changed from 1 Jan 2017 to 1 May 2017.